Clinical Trial

Selective Avoidance of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy In HER-2 Positive/Triple Negative Breast Cancer Patients With Excellent Radiologic Response to the Breast and Axilla, Prospective, Multi-center, Single-arm (ASLAN) Study

Study acronym: ASLAN
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The aims of this study is to evaluate 5 year recurrence free survival when omit sentinel lymph node biopsy after neoadjuvant chemotherapy in triple negative or HER-2 positive breast cancer patients when physical examination expected complete remission. And radiological expected Tumor size ≤ 2cm or non-mass enhancement ≤ 4cm.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-08-04; most recent amendment 2024-01-24.
Status change: Enrolling by Invitation → Active, Not Recruiting 2024-01-24
Status change: Recruiting → Enrolling by Invitation 2022-10-13
Status change: Not Yet Recruiting → Recruiting 2021-09-27
Trial Details
NCT Number NCT04993625
Lead Sponsor Jeong Eon Lee
Collaborators: Seoul National University Hospital, Severance Hospital, Gangnam Severance Hospital, Asan Medical Center
Conditions Breast Cancer
Enrollment 178 participants
Start Date 2021-09-27
Primary Completion 2028-12-31 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-01-26